ZTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zoetis Inc (ZTS) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company shows stable financial performance and long-term potential due to its market position and dividend growth, the lack of immediate growth catalysts, mixed analyst ratings, and neutral technical indicators suggest waiting for a clearer entry point.
The MACD is positive but contracting, RSI is neutral at 49.318, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 119, with resistance at 121.712 and support at 116.287.
Hedge funds are significantly increasing their positions in Zoetis, with a 228.26% increase in buying activity last quarter.
The company has consistently increased its dividends over the past decade, appealing to income-focused investors.
Citi initiated a Buy rating with a $145 price target, highlighting long-term growth potential driven by the 'humanization' pet trend.
Analysts have mixed views, with recent downgrades citing a lack of organic growth and an 'innovation air pocket' that could last 1-2 years.
Short-term underperformance in the stock price and market caution regarding its outlook.
Options data shows bearish sentiment with a high Option Volume Put-Call Ratio of 2.31.
In Q4 2025, Zoetis reported a 3.02% YoY revenue increase to $2.387 billion, a 3.79% YoY net income increase to $603 million, and a 6.98% YoY EPS growth to $1.38. Gross margin improved to 68.96%, up 1.38% YoY, indicating stable financial health.
Analyst ratings are mixed. Citi initiated a Buy rating with a $145 price target, citing long-term potential. However, Nephron Research and Piper Sandler downgraded the stock to Hold/Neutral, citing concerns about organic growth and innovation delays. BofA and UBS maintain Neutral ratings with price targets of $140 and $136, respectively.
